QED Therapeutics' Series A Round

QED Therapeutics raised a round of funding on January 30, 2018. Investors include BridgeBio Pharma.

QED Therapeutics is a biotechnology company focused on precision medicine for FGFR-driven disorders. Its lead candidate is infigratinib, a best-in-class FGFR kinase inhibitor that has shown meaningful…

Articles about QED Therapeutics' Series A Round: